Current status of FDG-PET/CT in staging of adult lymphoma

Abstract

Staging defines disease location and extent, suggests prognostic information and provides a baseline against which response or disease progression can be compared. Studies in Hodgkin (HL) and non-Hodgkin lymphoma (NHL) generally conclude that PET/CT is more accurate for diagnosing both nodal and extranodal disease than computed tomography (CT), thus having a strong potential impact on the staging of these lymphomas. Due to the high sensitivity and specificity of PET/CT in detecting bone marrow disease in newly diagnosed HL, bone marrow biopsy (BMB) is no longer indicated in HL; in aggressive NHL the detection of bone marrow involvement is still a topic of debate. In patients with a negative ..